Michael Bristow, MD, PhD

J Cardiac Failure

J Am coll Cardiol

Nature Clin Practice Cardiovasc Med 2:475-483.

J Human Mutation

Annals of Noninvasive Electrocardiology

Beta Blockers. In: The Pharmacologic Management of Chronic Heart Failure. Ed Feldman, AM, Blackwell Publishing

Adrenergic receptor coupling and uncoupling in heart failure. A textbook of Molecular Mechanisms of Cardiac Hypertrophy and Failure. Ed. Richard A Walsh M.D. Taylor and Francis

Circulation Suppl 112:II-673

Circulation Suppl 112:II-351

Suppl A. J Amer Col Card 47 (4) 936-191; 307A

Suppl A. J Amer Col Card 47 (4) 990-146;260A

Available on request

De Marco T, Wolfel E, Feldman AM, Lowes B, Higginbotham MB, Ghali JK, Wagoner L, Kirlin PC, Kennett JD, Goel S, Saxon LA, Boehmer JP, Mann D, Galle E, Ecklund F, Yong P, Bristow MR. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Cardiac Failure 14:9-18, 2008.

Haddad GE, Saunders LJ, Crosby SD, Carles M, del Monte F, King K, Bristow MR, Spinale FG, Macgillivray TE, Semigran MJ, Dec GW, Williams SA, Hajjar RJ, Gwathmey JK. Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences. Physiol Genomics 33:267-277. Epub 2008 Feb 26, 2008.

Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: Functional correlates. J Mol Cell Cardiol 45:185-192, 2008, Epub May 15.

Carnegie, GK, Soughayer J, Smith FD, Pedroja BS, Zhang F, Diviani D, Bristow MR, Kunkel MT, Newton AC, Langeberg LK, Scott JD. AKAP-Lbc Mobilizes a cardiac hypertrophy signaling pathway. Pharmacogenetics and Genomics, Mol Cell. 32(2):169-179, 2008.

Taylor MR, Slavov D, Humphrey K, Zhao, Cockroft J, Zhu X, Lavori P, Bristow MR, Mestroni L, Lazzeroni L. A pharmacogenetic effect of an endothelin-1 haplotype to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics 19:35-43, 2009.

Bristow MR and Hiatt WR. The FDA Regulatory process for drug and genetic diagnostic test approvals. Clinical and Translational Science, Volume 1, Issue 3, 188-189 December 2008.

Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O’Connor, Steinberg JS, Leigh J, Young P, Kosorok AM, Feldman D, DeMets D, Bristow MR. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure- Results from the COMPANION Trial. Circulation: Feb 9 2009, epub ahead of print.

Sharkey SW, Maron BJ, Nelson P, Parpart M, Maron MS, Bristow MR. Adrenergic Receptor Polymorphisms in Patients with Stress (Tako-Tsubo) Cardiomyopathy. Journal of Cardiology, 53(1), 53-57 February 2009

MacGregor JF, Blake Wachter S, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb;15(1):5-8.

Calalb MB, McKinsey TA, Newkirk S, Bohlmeyer T, Huynh K, PhD, Olson EN, Bristow MR. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. submitted.

Saxon LA, Olshansky B, Volosin K, Steinberg JS, Lee BK, Tomassoni G, Guarnieri T, Rao A, Yong P, Galle E, Leigh J, Ecklund F, Bristow MR. Influence of Left Ventricular Lead Location on Outcomes in the COMPANION Study. J Cardiovasc Electrophysiol. epub 26 Feb 2009

De Marco T, Lindenfeld J, Ghali J, Hesselson A, Flemming M, Galle L, Yong P, Bristow MR. Influence of sex on clinical outcomes with cardiac resynchronization therapy: Insights from the COMPANION Study. J Am Coll Cardiol;51(10 Suppl A):A71-1023-35. 2008.

Hatch JC, Buttrick PM, Nunley K, Bristow MR, Lowes BD. Regional Gene Expression Fingerprints of the Non-failing Human Heart. J Am Coll Cardiol;1(10 Suppl A):A38-1002-18. 2008.

. Zolty R, Cantu M, Horne BD, Lindenfeld J, Shakar SS, Wolfel EE, Brieke A, Lowes BD, Bristow MR. The Combination of beta-1 Arginine389 and alpha-2cDeleton322-325 Adrenergic Receptor Polymorphisms Demonstrate the Greatest Improvement in Left Ventricular Ejection Fracture on Beta-blockade Therapy in the African American Heart Failure Population. J Am Coll Cardiol;51(10 Suppl A):A47-1009-18. 2008.

. Carles MC, Saunders LJ, Del Monte F, Giana D, King KM, Crosby SD, Dobson JG, Bristow MR, Spinale FG, Pereira N, Dec GW, Semigran M, Macgillivray TE, Hajjar RJ, Gwathmey JK. J Am Coll Cardiol;51(10 Suppl A):A78-1030-29. 2008.

Mason, R.P., Kubant, R., Jacob, R.F., Jacoby, A.M., PortJ.D.,Bristow, M.R., and Malinski, T. Effect of the b3-receptor antagonist SR59230A on bucindolol-induced release of nitric oxide and peroxynitrite from human endothelium. Journal of Cardiac Failure 14(6), Supplement I:S76. 2008

Mason, R.P., Kubant, R., Jacob, R.F., Jacoby, A.M., Port, J.D., Bristow, M.R., and Malinski, T. Effects of bucindolol enantiomers on nitric oxide and peroxynitrite release from endothelial cells in ethnic populations. Journal of Cardiac Failure 14(6), Supplement I:S78. 2008

Walsh R, Farmer R, Kelly M, Nelson P, Morrison J, Port JD, Bristow MR. Human Myocardial ?1 389 Arg/Arg adrenergic receptors exhibit a propensity for constitutively active, high affinity agonist binding and are selectively inactivated by bucindolol. Journal of Cardiac Failure 14 Supplement I:S8, 2008.

De Marco T, Lee B, Lindenfeld J, Saxon LA, Boehmer J, Turakhia M, Leigh J, Yong P, Curran C, Feldman, Bristow MR. Influence of left ventricular end diastolic diameter index on clinical outcomes with cardiac resynchronization: Insights from the COMPANION study. Circulation 118(18) Suppl II- S950.

McGrew F, Boehmer J, Bank A, Galle E, Yong P, Leigh J, Bristow MR. Patterns in beta blocker use with cardiac resynchronization therapy: Insights from the COMPANION study. Circulation 118(18) Suppl II- S951.

Wolfel EE, De Marco T, Boehmer J, Lowes BD, Wagoner LE, Ghali JK, Thackeray L, Smith M, Yong P, Leigh J, Bristow MR. Effect of baseline peak oxygen consumption on clinical outcomes of cardiac resynchronization therapy: Findings from the COMPANION Exercise Performance Substudy. Circulation 118(18) Suppl II- S951.

Kawu SMt, Barr RG, Johnson C, Chahal H, Tandri H, Jain A, Kizer J, Bagiella E, Bristow MR, Lima J, Bluemke D. The relationship of inflammation and thrombosis with right ventricular mass and function: The MESA-Right Ventricle Study. AHA accepted abstract 2008.

Bristow MR, et al. Beta-Blocker Evaluation of Survival Trial (BEST) findings show benefit of bucindolol in moderate to severe HF patients, according to the pre-specified statistical analysis plan. J Am Coll Cardiol 2009 53: A157 .

O’Connor CM, Koch B, Fiuzat M, Davis G, Bristow MR, All-Cause Mortality Endpoint Comparison in Large Beta-Blocker Heart Failure Trials: United States (US) Versus Rest of World (ROW) J Am Coll Cardiol 2009 53: A154.

Brieke A, Shakar SF, Zolty R, Minobe W, Bristow MR, Lowes BD. Molecular remodeling on beta-blocker therapy in the failing human heart. Accepted abstract, ISHLT 29th Annual Meeting and Scientific Sessions 2009.

Articles 338. Movsesian M, StehlikJ, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 14(4), 255-263. 2009. 339. Taylor MR, Slavov D, Humphrey K, Zhao, Cockroft J, Zhu X, Lavori P, Bristow MR, Mestroni L, Lazzeroni L. A pharmacogenetic effect of an endothelin-1 haplotype to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics 19:35-43, 2009. 340. Bristow MR and Hiatt WR. The FDA Regulatory process for drug and genetic diagnostic test approvals. Clin Translational Sci 1:188-189, 2009. 341. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O’Connor, Steinberg JS, Leigh J, Young P, Kosorok AM, Feldman D, DeMets D, Bristow MR. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure- Results from the COMPANION Trial. Circulation 119:969-977, 2009. 342. Sharkey SW, Maron BJ, Nelson P, Parpart M, Maron MS, Bristow MR. Adrenergic receptor polymorphisms in patients with stress (Tako-Tsubo) cardiomyopathy. J Cardiol 53:53-57, 2009. 343. MacGregor JF, Blake Wachter S, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail 15: 5-8, 2009. 344. Saxon LA, Olshansky B, Volosin K, Steinberg JS, Lee BK, Tomassoni G, Guarnieri T, Rao A, Yong P, Galle E, Leigh J, Ecklund F, Bristow MR. Influence of left ventricular lead location on outcomes in the COMPANION Study. J Cardiovasc Electrophysiol 20:764-768, 2009 345. Calalb MB, McKinsey TA, Newkirk S, Bohlmeyer T, Huynh K, Sucharov CC, Bristow MR. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. Clin Translational Sci 2:325-332, 2009. 346. Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR for the ESSENTIAL Investigators. Effects of low-dose oral enoximone administration on mortality, morbidity and exercise capacity in patients with advanced heart failure. The randomised, double-blind, placebo-controlled, parallel group ESSENTIAL Trials. Eur Heart J 30:3015-3026, 2009. 347. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, and Liggett SB. An ?2C-adrenergic receptor polymorphism alters the norepinephrine lowering effects and therapeutic response of the beta blocker bucindolol in chronic heart failure. Circ Heart Fail 3:21-28, 2010. 348. Murphy G, Fiuzat M, Bristow MR. Targeting Heart Failure Therapeutics: A Historical Perspective. Heart Fail Clin 6:11-23, 2010 349. Kawut SM, Barr RG, Johnson WC, Chahal H, Tandri H, Jain A, Bristow MR, Kizer JR, Bagiella E, Lima JAC, Bluemke DA. MMP-9 and PAI-1 are associated with right ventricular structure and function: The MESA-RV Study. Submitted. 350. Cohen N, Patterson S, Spear B, Warner A, Wang D, Spoule R, Emison E, Spear B, Bristow MR, Barnes D, Bhathena A, Truter SL, Westelinck A, Russel C, Carl K, Pauling C, Peggy Wong M, Karnoub M, Okon IE, Shaw P Retrospective pharmacogenomics: analysis and regulatory decision making. Submitted Abstracts 335. Kawu SM, Barr RG, Johnson C, Chahal H, Tandri H, Jain A, Kizer J, Bagiella E, Bristow MR, Lima J, Bluemke D. The relationship of inflammation and thrombosis with right ventricular mass and function: The MESA-Right Ventricle Study. Circulation 118(18) Suppl II-5150, 2008. 336. Bristow MR, et al. Beta-Blocker Evaluation of Survival Trial (BEST) findings show benefit of bucindolol in moderate to severe HF patients, according to the pre-specified statistical analysis plan. J Am Coll Cardiol 53: A157 , 2009. 337. O’Connor CM, Koch B, Fiuzat M, Davis G, Bristow MR, All-cause mortality endpoint comparison in large beta-blocker heart failure trials: United States (US) versus Rest of World (ROW) J Am Coll Cardiol 53: A154, 2009. 338. Brieke A, Shakar SF, Zolty R, Minobe W, Bristow MR, Lowes BD. Molecular remodeling in beta-blocker therapy in the failing human heart. Accepted abstract, ISHLT 29th Annual Meeting and Scientific Sessions 2009. 339. Stees CS,Young E, Zolty R, Brieke A, Ferguson D, Minobe W, Shakar S, Bristow MR, Lowes BD. Electrical remodeling in response to beta blocker therapy. Heart Rhythm Society accepted abstract 2009. 340. Anand I, Fiuzat M, O’Connor C, Lindenfeld J, Carson P, Udelson J, Eric Eichhorn E, Domanski M, Davis G, Bristow MR. Impact of baseline volume status and LVEF on all-cause mortality in the BEST Trial. J Am Coll Cardiol, in press 2010. 341. Bristow MR, Taylor MR, Slavov D, Nelson P, Nunley K, Medway, AM, Sucharov CC. A polymorphism in the PDE3A gene promoter that prevents cAMP-induced increases in transcriptional activity, and may protect against PDE3A inhibitor drug tolerance. J Am Coll Cardiol, in press 2010. Book Chapters 44. Mestroni, L Bohlmeyer T, Gilbert EM, Bristow MR. Dilated Cardiomyopathies. Hurst’s the Heart, 13th Edition, McGraw-Hill NY, 2009. 45. Port JD, Sucharov CC, Bristow MR. Adrenergic Receptor Signaling in Chronic Heart Failure. Heart Failure: A companion to Braunwald’s Heart Disease (ed., Douglas L. Mann, M.D.) 2010. 46. Metra M, Bristow MR. Beta-blocker therapy in chronic heart failure. Heart Failure: A companion to Braunwald’s Heart Disease (ed., Douglas L. Mann, M.D.) 2010.

Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, and Liggett SB. An ?2C-adrenergic receptor polymorphism alters the norepinephrine lowering effects and therapeutic response of the beta blocker bucindolol in chronic heart failure. Circ Heart Fail 3:21-28, 2010. 348. Murphy G, Fiuzat M, Bristow MR. Targeting Heart Failure Therapeutics: A Historical Perspective. Heart Fail Clin 6:11-23, 2010. 349. Drakos SG, Abdallah G, Hammond EH, Reid BB, Revelo MP, Rasmusson BR, Whitehead KJ, Salama ME, Craig, Selzman H, Stehlik J, Bristow MR, Renlund DG, Li DY. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol (56) 382-39, 2010. 350. Carson P, Fiuzat M, O’Connor C, MD; Anand I, Plehn J, Lindenfeld J, Silver M, Michel White M, Alan Miller A, Davis G, Alastair D. Robertson AD, Bristow MR, Gottlieb S. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical Trial (BEST). In press, Am Heart J, 2010 351. Kawut SM, Barr RG, Johnson WC, Chahal H, Tandri H, Jain A, Bristow MR, Kizer JR, Bagiella E, Lima JAC, Bluemke DA. MMP-9 and PAI-1 are associated with right ventricular structure and function: The MESA-RV Study. Submitted. 2010 352. Cohen N, Patterson S, Spear B, Warner A, Wang D, Spoule R, Emison E, Spear B, Bristow MR, Barnes D, Bhathena A, Truter SL, Westelinck A, Russel C, Carl K, Pauling C, Peggy Wong M, Karnoub M, Okon IE, Shaw P Retrospective pharmacogenomics: analysis and regulatory decision making. Submitted. 2010 353. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella E, Cappola AR, Bristow MR, Johnson C, Kronmal RA, Kizer JR, Lima JA, Kawut SM. Sex hormones are associated with right ventricular structure and function: The MESA Right Ventricle. Am J Respir Crit Care Med. 2010 Oct 19. Epub ahead of print. 354. Bader FM, Gilbert EM, Mehta NA, Bristow MR. Double-blind, placebo-controlled comparison of enoximone and dobutamine Infusions in moderate to severe chronic heart failure ptients. Cong Heart Fail. Submitted. 2010 355. Dibble C, Lima J, Bluemke D, Chirinos J, Chahal H, Bristow MR, Kronmal R, Barr GR, Ferrari V, Propert K, Kawut S. Regional Left Ventricular Systolic Function and the Right Ventricle: The MESA-Right Ventricle Study. Submitted to Chest, in press 2011. 356. Kawut SM, Barr RG, Johnson WC, Chahal H, Tandri H, Jain A, Bristow MR, Kizer JR, Bagiella E, Lima JA, Bluemke DA. Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 Are associated with right ventricular structure and function: The MESA-RV Study. Biomarkers. 2010 Dec;15(8):731-8. Epub 2010 Oct 5. 357. Dockstader K, Nunley K, Medway AM, Nelson P, Liggett, Bristow MR, Sucharov CC. Analysis of Temporal Expression of mRNAs and miRNAs in Arg- and Gly389 Polymorphic Variants of the ß1-Adrenergic Receptor. Submitted to Physiological Genomics on 29th Dec 2010. 358. Bristow MR, O’Connor CM, Fiuzat M, Carson PE, Anand I, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Liggett SB. Combinatorial Pharmacogenetic Interactions of Bucindolol and ?1, ?2C Adrenergic Receptor Polymorphisms. Submitted 1-6-11 Circ CV Genetics. 359. Patterson SD, Cohen N, Karnoub M, Truter SL, Emison E, Khambata-Ford S, Spear B, Okony IE, Sproule R, Barnes D, Bhathena A, Bristow MR, Russell C, Wang D, Warner A, Westelinck A, Brian W, Snapir A, Franc MA, Wong P, Shaw PM. Prospective Retrospective Biomarker Analysis for Regulatory Consideration: A White Paper from the Industry Pharmacogenomics Working Group (I-PWG). Pharmacogenomics, in press. 2011

342. Anand I, Fiuzat M, O’Connor C, Lindenfeld J, Carson P, Udelson J, Eric Eichhorn E, Domanski M, Davis G, Bristow MR. Impact of baseline volume status and LVEF on all-cause mortality in the BEST Trial. J Am Coll Cardiol, Supp A, 55(10) A 2010 343. Bristow MR, Taylor MR, Slavov D, Nelson P, Nunley K, Medway, AM, Sucharov CC. A polymorphism in the PDE3A gene promoter that prevents cAMP-induced increases in transcriptional activity, and may protect against PDE3A inhibitor drug tolerance. J Am Coll Cardiol, Supp A, 55(10) A-37, 2010. 344. Lowes BD, Zolty R, Gilbert EM, Robertson AD , Bristow MR. Discovery and Validation of Novel Genes Predicting Cardiac Remodeling on ß-blockade. Circulation, 23 November 2010; 122: A17397. 345. Kao DP, Wagner DB, Robertson AD, Kittelson JM, Bristow MR, Lowes BD. High-dimensional clinical phenotype analysis predicts mortality and response to beta-blocker therapy in nonischemic heart failure, Accepted ACC 2011. 346. Tipney H, Kao DP, Bristow MR, Hunter LE, Lowes BD. Knowledge-based analysis implicates hypoxia in beta-blocker response. Accepted at AMIA Translational Bioinformatics Conference 2011. 347. Aleong R, Sauer W, Bristow MR. et al.. Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias with Bucindolol in Patients with Chronic Heart Failure. Accepted abstract #5287. Heart Rythem Society Meeting, 2011.

45. Port JD, Sucharov CC, Bristow MR. Adrenergic Receptor Signaling in Chronic Heart Failure. Heart Failure: A companion to Braunwald’s Heart Disease (ed., Douglas L. Mann, M.D.) 2010. 46. Metra M, Bristow MR. Beta-blocker therapy in chronic heart failure. Heart Failure: A companion to Braunwald’s Heart Disease (ed., Douglas L. Mann, M.D.) 2010.

19. "A Suite of mRNA Biomarkers Useful for Predicting the Efficacy of Beta-Blockers in an Individual Heart Failure Patient." Inventors Elaine Epperson and Michael Bristow. Provisional patent 61/722,062 submitted :11/2/12.

17. Bristow MR, Aleong RG. Treatment of the heart failure patient with atrial fibrillation: A major unmet need, J Am Coll Cardiol: Heart Fail, in press 2013.

N=12; 360. Bristow MR. Pharmacogenetic targeting of drugs for heart failure. Pharmacology and Therapeutics, 134:107-115, 2012 Epub 2012 Jan 16. 361. O’Connor CM, Fiuzat M, Carson PE, Anand I, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson PB, Medway AM, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and ?1, ?2C adrenergic receptor polymorphisms. PLOS ONE 7:e44324 epub Oct 10, 2012. 362. Kawut SM, Barr RG, JAC, Praestgaard A, Johnson WC, Chahal H, Ogunyankin KO, Bristow MR, Kizer JR, Tandri H, MD, and Bluemke DA. Right ventricular structure and function are associated with the risk of heart failure and cardiovascular death: The MESA-Right Ventricle Study. Circulation 126:1681-1688, 2012. 363. Leary PJ, Barr G, Bluemke DA, Bristow MR, Hough CL, Kronmal RA, Lima JA, McClelland RL, Tracy RP, Kawut SM Von Willebrand Factor and the right ventricle: The MESA-Right Ventricle Study. Am J Cardiol Sep 18. pii: S0002-9149(12)01951-0. doi: 10.1016/j.amjcard.2012. 364. Ventetuolo CE, Lima JAC, Barr RG, Bristow MR, Bagiella E, Chahal H, Kizer JR, Lederer DJ, Bluemke DA, Kawut SM. The renin-angiotensin system and right ventricular structure and function: The MESA-Right Ventricle Study. Pulm Circ 2:379, 386, 2012. 365. Musunuru D, Roden D, Boineau R, Bristow MR, McCaffrey TA, Newton-Cheh C, Paltoo DN, Rosenberg Y, Wohlgemuth JG, Zineh I, Hasan AK. Cardiovascular pharmacogenomics: Current status and future directions ? Report of a National Heart, Lung, and Blood Institute Working Group. J Am Heart Assoc Apr;1(2):e000554. doi: 10.1161/JAHA.111.000554. Epub 2012 Apr 24. 366. Kao DP, Davis G, MS, Aleong R, O’Connor CM, Mona Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, MD, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail ePub Dec 7, 2012 doi:10.1093/eurjhf/hfs181. 367. Kao DP, Wagner BD, Robertson AD, Bristow MR, Lowes BD. A Personalized BEST: Characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLOS ONE 7: e48184. epub Nov 7, 2012. 368. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol in press, 2012. 369. Fiuzat M, O’Connor C, Guyffier F, Mascette A, Geller N, Mebazaa A, Voors A, Adams K, Pina I, Neyses L, Muntendam P, Felker M, Pitt B, Zannad F, Bristow MR. Personalized medicine in heart failure, a forum for unified strategies. Submitted. 370. Feldman AM, Mann DL, She L, Bristow MR, Maisel AS, McNamara DM, Walsh R, Lee DL, Wos S, Lang I, Wells G, Drazner MH, Schmedtje JF, Pauly DF, Sueta CA, Di Maio M, Kron IL, Velazquez EJ, Lee KL. The prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: Results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) Trials. Circulation, submitted. 371. Cohen N, Patterson S, Spear B, Warner A, Wang D, Spoule R, Emison E, Spear B, Bristow MR, Barnes D, Bhathena A, Truter SL, Westelinck A, Russel C, Carl K, Pauling C, Peggy Wong M, Karnoub M, Okon IE, Shaw P. Retrospective pharmacogenomics: analysis and regulatory decision making. Submitted. 372. Aleong RG, Sauer WH, Davis G, Murphy GA, PhD, Port JD, PhD, Abraham WT, Liggett SB, Bristow MR. Prevention of atrial fibrillation by bucindolol is dependent on the beta-1 389 Arg/Gly adrenergic receptor polymorphism. Submitted.

N=6; 354. Aleong R, Davis G, Sauer W, Bristow MR. Bucindolol's sympatholytic properties contribute to reduction in the risk of developing new onset atrial fibrillation in patients with advanced heart failure. J Am Coll Cardiol 59:A166, 2012. 355. Kao DP, Zolty R, Gilbert EM, Lowes BD, Bristow MR. Myocardial gene expression associated with right- and left-ventricular remodeling with beta-blockade in idiopathic dilated cardiomyopathy. HFSA 2012 annual scientific meeting, J Cardiac Failure, J of Card Fail S33-34. 18(8) Supp 1 Aug 2012 356. Kao D, Davis G, Aleong R, Sauer W, Bristow MR. Effect of Bucindolol on Heart Failure Outcomes and Ventricular Response Rate in HFREF Patients with Permanent Atrial Fibrillation. HFSA 2012 annual scientific meeting, J Cardiac Failure, #162; S50-51. 18(8) Supp 1 Aug 2012. 357. Kao DP, Epperson LE, Karimpous-Fard A, Gilbert EM, Lowes B, Hunter LE, Bristow MR. Transcription of select homeobox genes increases in patients with heart failure-reduced ejection fraction who have improvements in left ventricular ejection fraction on {beta}-blocker therapy. Circulation 126:A14777, 2012. 358. Kao DP, Epperson LE, Karimpous-Fard A, Gilbert EM, Lowes B, Hunter LE, Bristow MR. Changes in expression of cholesteryl ester transfer protein (CETP) are correlated with improvement in left ventricular function in patients with heart failure and reduced ejection fraction who respond to ß-blocker therapy. Circulation 126:A14639, 2012. 359. Hinterberg MA, Kao DP, Karimpour-Fard A, Sucharov CC, Hunter LE, Port JD, Bristow MR. Myocardial Expression of the MicroRNA Dre-mir-133a-5p is Associated with Improvement in Left Ventricular Ejection Fraction in Patients with Idiopathic Dilated Cardiomyopathy Treated with Beta-Blockers. Accepted ACC 2013

Bristow MR, Aleong RG. Treatment of the heart failure patient with atrial fibrillation: a major unmet need. JACC Heart Fail. 2013 Feb;1(1):29-30. PubMed PMID: 24621796

Aleong RG, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR. Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta(1)389 Arg/Gly Adrenergic Receptor Polymorphism. JACC Heart Fail. 2013 Aug 1;1(4):338-344. PubMed PMID: 24159564

Fiuzat M, O'Connor CM, Gueyffier F, Mascette AM, Geller NL, Mebazaa A, Voors AA, Adams KF, Piña IL, Neyses L, Muntendam P, Felker GM, Pitt B, Zannad F, Bristow MR. Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail. 2013 Aug;19(8):592-9. PubMed PMID: 23910590

Feldman AM, Mann DL, She L, Bristow MR, Maisel AS, McNamara DM, Walsh R, Lee DL, Wos S, Lang I, Wells G, Drazner MH, Schmedtje JF Jr, Pauly DF, Sueta CA, Di Maio M, Kron IL, Velazquez EJ, Lee KL. Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials. Circ Heart Fail. 2013 May;6(3):461-72. PubMed PMID: 23584092

Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013 Feb;6(1):137-43. PubMed PMID: 23275278

Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar;15(3):324-33. PubMed PMID: 23223178

Bristow MR, Quaife RA. The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series). Pulm Circ. 2015 Sep;5(3):415-23. PubMed PMID: 26401244

Vehlow C, Kao DP, Bristow MR, Hunter LE, Weiskopf D, Görg C. Visual analysis of biological data-knowledge networks. BMC Bioinformatics. 2015 Apr 29;16:135. PubMed PMID: 25925016

Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM. Cardiovascular drug development: is it dead or just hibernating?. J Am Coll Cardiol. 2015 Apr 21;65(15):1567-82. PubMed PMID: 25881939

Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE, Meyer LK, Ferguson DA, Volkman AK, Zolty R, Borg CD, Quaife RA, Bristow MR. Therapeutic Molecular Phenotype of ß-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. Circ Cardiovasc Genet. 2015 Apr;8(2):270-83. PubMed PMID: 25637602

Hinterberg MA, Kao DP, Bristow MR, Hunter LE, Port JD, Görg C. Peax: interactive visual analysis and exploration of complex clinical phenotype and gene expression association. Pac Symp Biocomput. 2015;:419-30. PubMed PMID: 25592601

384. Lindenfeld J, Cleveland JC Jr, Kao DP, White M, Wichman S, Bristow JC, Peterson V, Rodegheri-Brito J, Korst A, Blain-Nelson P, Sederberg J, Hunt SA, Gilbert EM, Ambardekar AV, Minobe W, Port, JD, Bristow MR. Sex-related differences in age-associated down-regulation of human ventricular myocardial ?1-adrenergic receptors. J Heart Lung Transplant 35:352-61, 2016. PMID: 2697047, PMCID pending. 385. Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heckbert SR, Kawut SM, Krieger EV, Lima JA, Masri CS, Ralph DD, Shea S, Weiss NS, Kronmal RA. Histamine H2-receptor antagonists, left ventricular morphology and the risk for heart failure: The Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 67:1544-52, 2016. PMID:27150686 386. Bristow MR, Saxon LA, Feldman AM, Mei C, MD, Anderson SA, DeMets DL. Lessons learned and insights gained in the design, analysis and outcomes of the COMPANION trial. JACC-Heart Fail 4:521-35, 2016. 387. Bristow MR, Enciso JS, Gersh BJ, Grady C, Rice MM, Singh S, Greenberg BH. Detection and management of geographic disparities in the TOPCAT trial: Lessons learned and derivative recommendations. J Am Coll Cardiol Basic Transl Science 1:180–189, 2016. NIHMS 785007, PMID: 27747305, PMCID: PMC5065247. 388. Breathett KK, Allen LA, Udelson J, Davis G, Bristow MR. Changes in left ventricular ejection fraction predict survival and hospitalization in heart failure with reduced ejection fraction. Circ Heart Fail. 2016;9:e002962 originally published September 21, 2016,doi:10.1161. 389. Bristow MR, Sharma K, Assmann SF, Linas S, Gersh BJ, Grady C, Rice MM, Singh S, Boineau R, Rosenberg Y, McKinlay SM, Greenberg BH. Data and safety monitoring board evaluation and management of a renal adverse events signal in TOPCAT. Eur J Heart Fail. 2016 Nov 21. doi: 10.1002/ejhf.686. [Epub ahead of print]. 390. Sucharov CC, Kao DP, Port JD, Karimpour-Fard A, Quaife RA, Minobe W, Nunley K, Lowes BD, Gilbert EM, Bristow MR. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight, 2(2):e89169s 1-16, 2017 doi:10.1172. 391. Sucharov CC, Nakano SJ, Slavov D, Nunley K, Medway A, Nelson P, McKinsey TA, Movsesian M, Taylor MR, Bristow MR. Identification of a polymorphism in the PDE3A gene promoter that regulates cAMP-induced increases in transcriptional activity and affects cAMP depletion in failing human heart. Submitted.

Aleong RG, Kao DP, Lowes BD, Minobe W, Gilbert EM, Bristow MR. Ventricular myocardial gene expression in HFrEF patients with atrial fibrillation (AF) vs. no AF, and changes in response to beta-blockade. Circulation. 2017;136 Supp l A17316.

Butler M, Kao D, Lowes B, Gilbert EM, Minobe W, Meyer L, Ferguson D, Zolty R, Robertson A, Quaife R, Bristow MR. Alpha2-C adrenergic receptor genotype is strongly associated with changes in the beta1-gene signaling network in nonsichemic dilated cardiomyopathy patients undergoing beta-blocker therapy. (AHA 2017). Volume 136, Issue Suppl 1. Circulation. 136:A15921

Sweet ME, Cocciolo A, Slavov D, Graw SL, Jones KL, Reece TB, Ambardekar AV, Bristow MR. RNA-seq Identifies Shared and Divergent Expression Signatures of Heart Failure in Human Heart Tissue. (AHA 2017) Circulation Volume 136, Issue Suppl 1 136:A18613

Butler M, Kao DP, Lowes BD, Minobe W, Gilbert EM, Bristow MR. Expression of the beta-1-adrenergic receptor gene signaling network is more dysregulated in reduced ejection fraction vs. mid-range ejection fraction heart failure. (AHA 2017). Volume 136, Issue Suppl 1. Circulation. 2017;136:A16914

Sucharov CC, Kao DP, Port JD, Karimpour-Fard A, Quaife RA, Minobe W, Nunley K, Lowes BD, Gilbert EM, Bristow MR. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight, 2(2):e89169s 1-16, 2017 doi:10.1172.

Kalscheur MM, Saxon LA, Lee BK, Steinberg JS, Mei C, Buhr KA, DeMets DL, Bristow MR, Singh SN. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION Trial. Heart Rhythm, 14(6):858-65, 2017.

Sucharov CC, Nakano SJ, Slavov D, Nunley K, Medway A, Stafford N, McKinsey TA, Movsesian M, Minobe W, Taylor MRG, Bristow MR. A novel polymorphism in the PDE3A gene promoter regulates cAMP-induced transcriptional activity and cAMP levels in failing human heart. Sci Transl Med, in revision.

Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Velduisen DJ, Sauer WH, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR. A Genotype-directed comparative Effectiveness TrIal of buCindolol and Toprol-XL for prevention of symptomatic Atrial Fibrillation/Atrial Flutter in patients with heart failure: Rationale and design of the GENETIC-AF Trial. Am Heart J, in press.

Shah P, Bristow MR, Port JD. MicroRNAs in heart failure, cardiac transplantation and myocardial recovery: Biomarkers with therapeutic potential. Curr Heart Fail Rep. 14(6):454-64, 2017.

Bristow MR, Kao DP, Breathett KK, Altman NL, MD, Gorcsan J 3rd, Gill EA, MD, Lowes BD, Gilbert EM, Quaife RA, Mann DL. Structural and functional phenotyping of the failing heart: Is the left ventricular ejection fraction obsolete? JACC-Heart Fail 5:772-781, 2017.

Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jones KL, Kao DP, Kawut SM, Krieger EV, Lima JA, Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. Histamine H2 receptor polymorphisms, myocardial transcripts and heart failure, From The Multi-Ethnic Study of Atherosclerosis and Beta-blocker Effect on Remodeling and Gene Expression Trial. Am J Cardiol 121(2):256-261, 2018.

O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. Improving heart failure therapeutics development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol 71:443-453, 2018

Bristow MR, Leinwand LA, Olson EN. Entrepreneurialism in the translational biologic sciences: Why, how and however. JACC: Basic Transl Sci, in press (Feb 25, 2018).

Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF, Felker GM Liggett SB, O’Connor CM, MD, Bristow MR. Dose-response of beta-blockers in adrenergic receptor polymorphism genotypes. Submitted.

Sweet ME, Cocciolo A, Slavov D, Graw SL, Jones KL Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG. Shared and divergent transcriptomic signatures in human heart failure. Submitted.

BegayRL, Graw SL, Sinagra G, Asimaki A, Rowland TJ, Slavov DB, Gowan K, Jones KL, Brun F, Merlo M, Miani D, Sweet M, Devaraj K, Wartchow EP, Gigli M, Puggia I, Salcedo EE, Deborah M. Garrity DM, AmbardekarAV, Bristow MR, Saffitz JE, Mestroni L, Taylor MRG. Filamin C truncation mutations are associated with arrhythmogenic dilated cardiomyopathy and changes in the cell-cell adhesion structures. Submitted.

Aleong RG, Ambardekar A; Khazanie P; Sauer WH, Marshall D, Davis G, Bristow MR. Bucindolol prevention of atrial flutter is influenced by the ADRB1 Arg389Gly Polymorphism. Submitted.

Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Boehmer J, Tavazzi L, Gras D, Saxon L, Ghio S, DeMets D, Feldman AM Daubert J-C. Cardiac resynchronization pacemakers for patients with heart failure: An individual patient-data meta-analysis from COMPANION and CARE-HF. Submitted.

Myers VD, Gerhard GS, McNamara DM,…..Bristow MR, …Feldman AM. Novel functional variants in BAG3 found selectively in African Americans predict a worse outcome with dilated cardiomyopathy. Submitted.

Bristow MR. Genetic variation expressed in the brain may impact heart failure. Eur J Heart Fail 19:324-325, 2017.

Bristow MR, Altman NL. Heart rate in preserved ejection fraction heart failure, JACC Heart Fail S2213-1779, 2017.

Bristow MR. Contractile reserve and the response to cardiac resynchronization therapy. Int J Cardiol 252:234-235, 2018.

Sweet ME, Cocciolo A, Slavov D, Jones KL, Sweet JR, Graw SL, Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG. Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure. BMC Genomics. 2018 Nov 12;19(1):812. PubMed PMID: 30419824

Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF Jr, Felker GM, Liggett SB, O'Connor CM, Bristow MR. Dose Response of ß-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med. 2018 Aug;11(8):e002210. PubMed PMID: 30354340

Myers VD, Gerhard GS, McNamara DM, Tomar D, Madesh M, Kaniper S, Ramsey FV, Fisher SG, Ingersoll RG, Kasch-Semenza L, Wang J, Hanley-Yanez K, Lemster B, Schwisow JA, Ambardekar AV, Degann SH, Bristow MR, Sheppard R, Alexis JD, Tilley DG, Kontos CD, McClung JM, Taylor AL, Yancy CW, Khalili K, Seidman JG, Seidman CE, McTiernan CF, Cheung JY, Feldman AM. Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiol. 2018 Oct 1;3(10):929-938. PubMed PMID: 30140897

Begay RL, Graw SL, Sinagra G, Asimaki A, Rowland TJ, Slavov DB, Gowan K, Jones KL, Brun F, Merlo M, Miani D, Sweet M, Devaraj K, Wartchow EP, Gigli M, Puggia I, Salcedo EE, Garrity DM, Ambardekar AV, Buttrick P, Reece TB, Bristow MR, Saffitz JE, Mestroni L, Taylor MRG. Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell-Cell Adhesion Structures. JACC Clin Electrophysiol. 2018 Apr;4(4):504-514. PubMed PMID: 30067491

Bristow MR, Leinwand LA, Olson EN. Entrepreneurialism in the Translational Biologic Sciences: Why, How, and However. JACC Basic Transl Sci. 2018 Feb;3(1):1-8. PubMed PMID: 30062188

Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen DJ, Sauer WH, White M, Wilton SB, Anand IS, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. Am Heart J. 2018 May;199:51-58. PubMed PMID: 29754666

Haywood ME, Cocciolo A, Porter KF, Dobrinskikh E, Slavov D, Graw SL, Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG. Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53. J Mol Cell Cardiol. 2020 Feb;139:124-134. PubMed PMID: 31958463

Sucharov CC, Nakano SJ, Slavov D, Schwisow JA, Rodriguez E, Nunley K, Medway A, Stafford N, Nelson P, McKinsey TA, Movsesian M, Minobe W, Carroll IA, Taylor MRG, Bristow MR. A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium. J Am Coll Cardiol. 2019 Mar 19;73(10):1173-1184. PubMed PMID: 30871701

O'Connor CM, Bristow MR. Changing the Research Culture in the United States. JACC Heart Fail. 2018 Apr;6(4):344-345. PubMed PMID: 29598937

Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ. Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 Jul;7(7):586-598. PubMed PMID: 31042551

O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol. 2018 Jan 30;71(4):443-453. PubMed PMID: 29389362

Bristow MR. Contractile reserve and the response to cardiac resynchronization therapy. Int J Cardiol. 2018 Feb 1;252:234-235. PubMed PMID: 29249434

Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jones KL, Kao DP, Kawut SM, Krieger EV, Lima JA, Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. Histamine H(2) Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). Am J Cardiol. 2018 Jan 15;121(2):256-261. PubMed PMID: 29191567

Shamoun F, De Marco T, DeMets D, Mei C MS, Lindenfeld J, Saxon LA, Boehmer JP, Leigh J, Yong P, Feldman AM, Bristow MR. Impact of degree of left ventricular remodeling on clinical outcomes from cardiac resynchronization therapy. JACC: Heart Fail, in press.

Sucharov CC, Nakano SJ, Slavov D, Nunley K, Medway A, Stafford N, McKinsey TA, Movsesian M, Minobe W, Taylor MRG, Bristow MR. A novel polymorphism in the PDE3A gene promoter regulates cAMP-induced transcriptional activity and cAMP levels in failing human heart. J Am Coll Cardiol, in press.

Shamoun F, De Marco T, DeMets D, Mei C, Lindenfeld J, Saxon LA, Boehmer JP, Leigh J, Yong P, Feldman AM, Bristow MR. Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy. JACC Heart Fail. 2019 Apr;7(4):281-290. PubMed PMID: 30738980

Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Boehmer J, Tavazzi L, Gras D, Saxon L, Ghio S, DeMets D, Feldman AM Daubert J-C. Cardiac resynchronization pacemakers for patients with heart failure: An individual patient-data meta-analysis from COMPANION and CARE-HF.

Aleong RG, Ambardekar A; Khazanie P; Sauer WH, Marshall D, Davis G, Bristow MR. Bucindolol prevention of atrial flutter is influenced by the ADRB1 Arg389Gly Polymorphism.

Abraham WT, MD, Piccini JP, MD, Rienstra M, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, MD7, Wranicz JK, Bristow MR, Connolly S, MD, on behalf of the Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Trial Investigators. Phase II Trial of Pharmacogenetic Guided Beta-Blocker Therapy with Bucindolol vs. Metoprolol for the Prevention of Atrial Fibrillation/Flutter in Heart Failure: GENETIC-AF. ESC-Heart failure Meeting, Vienna, AT, 2018 (Eur J Heart Failure 20:S1 abstract 674, 2018).

Piccini JP, Abraham WT, Healey JS….Bristow MR, Connolly S. Phase II Trial of Pharmacogenetic Guided Beta-Blocker Therapy With Bucindolol vs. Metoprololfor the Prevention of Atrial Fibrillation/Flutter in Heart Failure:GENETIC-AF AF Burdent Substudy. Abstract Su4080, Circulation:

Toni LS, Carroll IA, Jones KL, Schwisow JA, Minobe WA, Rodriguez EM, Altman NL, Lowes BD, Gilbert EM, Buttrick PM, Kao DP, Bristow MR. Correction: Sequential analysis of myocardial gene expression with phenotypic change: Use of cross-platform concordance to strengthen biologic relevance. PLoS One. 2019;14(10):e0224389. PubMed PMID: 31639152

Toni LS, Carroll IA, Jones KL, Schwisow JA, Minobe WA, Rodriguez EM, Altman NL, Lowes BD, Gilbert EM, Buttrick PM, Kao DP, Bristow MR. Sequential analysis of myocardial gene expression with phenotypic change: Use of cross-platform concordance to strengthen biologic relevance. PLoS One. 2019;14(8):e0221519. PubMed PMID: 31469842

O'Connor CM, Bristow MR. Changing U.S. Heart Failure Research Culture: Part 2-Recognizing Frontline Investigators and Coordinators. JACC Heart Fail. 2020 Dec;8(12):1050-1051. PubMed PMID: 33272381

Bristow MR, Zisman LS, Altman NL, Gilbert EM, Lowes BD, Minobe WA, Slavov D, Schwisow JA, Rodriguez EM, Carroll IA, Keuer TA, Buttrick PM, Kao DP. Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. JACC Basic Transl Sci. 2020 Sep;5(9):871-883. PubMed PMID: 32838074

Haywood ME, Cocciolo A, Porter KF, Dobrinskikh E, Slavov D, Graw SL, Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG. Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53. J Mol Cell Cardiol. 2020 Feb;139:124-134. PubMed PMID: 31958463

Chung MK, Zidar D, Bristow MR, Cameron S, Chan T, Harding CV, Kwon DH, Singth T, Tilton J, Tsai EJ, Tucker NR, Barnard J, Loscalzo J. COVID-19 and Cardiovascular Disease: from Bedside to Bench to Bedside. Circulation, in press. 2021.

Knight WE, Cao Y, Ying-Hsi L, Sparagna GC, Bai B, Zhao Y, Chi C, Du Y, Londono P, Reisz JA, Brown BC, Taylor MRG, Abardekar AV, Cleveland JC, McKinsey TA, Jeong MY, Walker LA, Woulfe KC, D’ Alessandro A, Bristow MR, Buttrick PM, Song K. Maturation of human induced pluripotent stem cell-derived cardiomyocytes for modeling hypertrophic cardiomyopathy. doi: https://doi.org/10.1101/2020.01.16.909598 Stem Cell Reports, in press. 2021

Piccini JP, MD, Healey JS, Abraham WT, ……Bristow MR, Connolly SJ. Pharmacogenomic guided beta-blocker therapy with bucindolol reduces atrial fibrillation burden compared to metoprolol succinate: The GENETIC-AF Trial. HRS 2020.

Healey JS, Piccini JP, Abraham WT, ……Bristow MR, Connolly SJ. Impact of pharmacogenetic-guided bucindolol versus metoprolol succinate on the overall burden of clinical events in patients with atrial fibrillation and heart failure: The GENETIC-AF Trial. HRS 2020.

Abraham WT, Bristow MR, Piccini JP,………..Dufton C, Connolly SJ. Bucindolol is associated with a lower Incidence of dose limiting bradycardia in heart failure patients with atrial fibrillation: The GENETIC-AF Trial. HRS 2020.

Li H, Trager LE, Liu X, Hastings MH, Xiao C, Guerra J, To S, Li G, Yeri A, Rodosthenous R, Silverman MG, Das S, Ambardekar AV, Bristow MR, Gonzalez-Rosa JM, Rosenzweig A. lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth. Circulation. 2022 Feb 4. [Epub ahead of print] PubMed PMID: 35114812

Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J. 2022 Jan 2;246:136-143. [Epub ahead of print] PubMed PMID: 34986394

Gao S, Mumme-Monheit A, Chen SN, Spector EB, Slavov D, Baralle FE, Bristow MR, Mestroni L, Taylor MRG. An LMNA synonymous variant associated with severe dilated cardiomyopathy: Case report. Am J Med Genet A. 2022 Feb;188(2):600-605. PubMed PMID: 34652067

Leopold JA, Kawut SM, Aldred MA, Archer SL, Benza RL, Bristow MR, Brittain EL, Chesler N, DeMan FS, Erzurum SC, Gladwin MT, Hassoun PM, Hemnes AR, Lahm T, Lima JAC, Loscalzo J, Maron BA, Rosa LM, Newman JH, Redline S, Rich S, Rischard F, Sugeng L, Tang WHW, Tedford RJ, Tsai EJ, Ventetuolo CE, Zhou Y, Aggarwal NR, Xiao L. Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circ Heart Fail. 2021 Jun;14(6). PubMed PMID: 34422205

Piccini JP, Dufton C, Carroll IA, Healey JS, Abraham WT, Khaykin Y, Aleong R, Krueger SK, Sauer WH, Wilton SB, Rienstra M, van Veldhuisen DJ, Anand IS, White M, Camm AJ, Ziegler PD, Marshall D, Bristow MR, Connolly SJ. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol. 2021 Aug;14(8):e009591. PubMed PMID: 34270905

Woulfe KC, Jeffrey DA, Pires Da Silva J, Wilson CE, Mahaffey JH, Lau E, Slavov D, Hailu F, Karimpour-Fard A, Dockstader K, Bristow MR, Stauffer BL, Miyamoto SD, Sucharov CC. Serum response factor deletion 5 regulates phospholamban phosphorylation and calcium uptake. J Mol Cell Cardiol. 2021 Oct;159:28-37. PubMed PMID: 34139234

Hailu FT, Karimpour-Fard A, Toni LS, Bristow MR, Miyamoto SD, Stauffer BL, Sucharov CC. Integrated analysis of miRNA-mRNA interaction in pediatric dilated cardiomyopathy. Pediatr Res. 2021 May 19. [Epub ahead of print] PubMed PMID: 34012027

Das M, Bristow MR, Chung MK. The Essential Vulnerability of Human Cardiac Myocytes to SARS-CoV-2. JACC Basic Transl Sci. 2021 Apr;6(4):346-349. PubMed PMID: 33997520

Doran B, Mei C, Varosy PD, Kao DP, Saxon LA, Feldman AM, DeMets D, Bristow MR. The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy. JACC Heart Fail. 2021 Jun;9(6):439-449. PubMed PMID: 33992570

Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV 3rd, Kwon DH, Singh T, Tilton JC, Tsai EJ, Tucker NR, Barnard J, Loscalzo J. COVID-19 and Cardiovascular Disease: From Bench to Bedside. Circ Res. 2021 Apr 16;128(8):1214-1236. PubMed PMID: 33856918

Knight WE, Cao Y, Lin YH, Chi C, Bai B, Sparagna GC, Zhao Y, Du Y, Londono P, Reisz JA, Brown BC, Taylor MRG, Ambardekar AV, Cleveland JC Jr, McKinsey TA, Jeong MY, Walker LA, Woulfe KC, D'Alessandro A, Chatfield KC, Xu H, Bristow MR, Buttrick PM, Song K. Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic Cardiomyopathy. Stem Cell Reports. 2021 Mar 9;16(3):519-533. PubMed PMID: 33636116

Rubino M, Travers JG, Headrick AL, Enyart BT, Lemieux ME, Cavasin MA, Schwisow JA, Hardy EJ, Kaltenbacher KJ, Felisbino MB, Jonas E, Ambardekar AV, Bristow MR, Koch KA, McKinsey TA. Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart. Circ Res. 2023 Jan 6;132(1):10-29. PubMed PMID: 36475698

Altman NL, Berning AA, Saxon CE, Adamek KE, Wagner JA, Slavov D, Quaife RA, Gill EA, Minobe WA, Jonas ER, Carroll IA, Huebler SP, Raines J, Messenger JC, Ambardekar AV, Mestroni L, Rosenberg RM, Rove J, Campbell TB, Bristow MR. Myocardial Injury and Altered Gene Expression Associated With SARS-CoV-2 Infection or mRNA Vaccination. JACC Basic Transl Sci. 2022 Oct 19. [Epub ahead of print] PubMed PMID: 36281440

Zhao Y, Riching AS, Knight WE, Chi C, Broadwell LJ, Du Y, Abdel-Hafiz M, Ambardekar AV, Irwin DC, Proenza C, Xu H, Leinwand LA, Walker LA, Woulfe KC, Bristow MR, Buttrick PM, Song K. Cardiomyocyte-Specific Long Noncoding RNA Regulates Alternative Splicing of the Triadin Gene in the Heart. Circulation. 2022 Aug 30;146(9):699-714. PubMed PMID: 35862102

Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Gras D, Saxon L, Tavazzi L, Boehmer J, Ghio S, Feldman AM, Daubert JC, de Mets D. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF. Eur J Heart Fail. 2022 Jun;24(6):1080-1090. PubMed PMID: 35490339

Annex BH, Bristow MR, Frangogiannis NG, Kelly DP, Kontaridis MI, Libby P, Robb MacLellan W, McNamara CA, Mann DL, Pitt GS, Sipido KR. JACC: Basic to Translational Science Top Reviewers 2021: With Appreciation. JACC Basic Transl Sci. 2022 Feb;7(2):192. PubMed PMID: 35257046

Bristow MR, Mann DL. Cardiac Adrenergic Activation in Heart Failure With Preserved Ejection Fraction: A Role for ß-Blockade?. JACC Basic Transl Sci. 2022 Feb;7(2):128-130. PubMed PMID: 35257039

Abraham WT, Piccini JP, Dufton C, Carroll IA, Healey JS, O'Connor CM, Marshall D, Aleong R, van Veldhuisen DJ, Rienstra M, Wilton SB, White M, Sauer WH, Anand IS, Huebler SP, Connolly SJ, Bristow MR. Dose-limiting, adverse event-associated bradycardia with ß-blocker treatment of atrial fibrillation in the GENETIC-AF trial. Heart Rhythm O2. 2022 Feb;3(1):40-49. PubMed PMID: 35243434

Chen SN, Lam CK, Wan YW, Gao S, Malak OA, Zhao SR, Lombardi R, Ambardekar AV, Bristow MR, Cleveland J, Gigli M, Sinagra G, Graw S, Taylor MRG, Wu JC, Mestroni L. Activation of PDGFRA signaling contributes to filamin C-related arrhythmogenic cardiomyopathy. Sci Adv. 2022 Feb 25;8(8):eabk0052. PubMed PMID: 35196083

Li H, Trager LE, Liu X, Hastings MH, Xiao C, Guerra J, To S, Li G, Yeri A, Rodosthenous R, Silverman MG, Das S, Ambardekar AV, Bristow MR, González-Rosa JM, Rosenzweig A. lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth. Circulation. 2022 Apr 19;145(16):1218-1233. PubMed PMID: 35114812

Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J. 2022 Apr;246:136-143. PubMed PMID: 34986394

Gao S, Mumme-Monheit A, Chen SN, Spector EB, Slavov D, Baralle FE, Bristow MR, Mestroni L, Taylor MRG. An LMNA synonymous variant associated with severe dilated cardiomyopathy: Case report. Am J Med Genet A. 2022 Feb;188(2):600-605. PubMed PMID: 34652067

Hailu FT, Karimpour-Fard A, Toni LS, Bristow MR, Miyamoto SD, Stauffer BL, Sucharov CC. Integrated analysis of miRNA-mRNA interaction in pediatric dilated cardiomyopathy. Pediatr Res. 2022 Jul;92(1):98-108. PubMed PMID: 34012027

Annex BH, Bristow MR, Frangogiannis NG, Kelly DP, Kontaridis M, Libby P, MacLellan WR, McNamara CA, Mann DL, Pitt GS, Sipido KR. JACC: Basic to Translational Science Top Reviewers 2023: With Appreciation and Gratitude. JACC Basic Transl Sci. 2024 Jan;9(1):161. PubMed PMID: 38362353

Martin TG, Pak H, Gerhard GS, Merali S, Merali C, Lemster B, Dubey P, McTiernan CF, Bristow MR, Feldman AM, Kirk JA. Dysregulated Autophagy and Sarcomere Dysfunction in Patients With Heart Failure With Co-Occurrence of P63A and P380S BAG3 Variants. J Am Heart Assoc. 2023 Dec 19;12(24):e029938. PubMed PMID: 38108245

Dimond MG, Ibrahim NE, Fiuzat M, McMurray JJV, Lindenfeld J, Ahmad T, Bozkurt B, Bristow MR, Butler J, Carson PE, Felker GM, Jessup M, Murillo J, Kondo T, Solomon SD, Abraham WT, O'Connor CM, Psotka MA. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping. JACC Heart Fail. 2023 Nov 28. [Epub ahead of print] PubMed PMID: 38099892

Lefkowitz RJ, Rockman HA, Shim PJ, Liu S, Ahn S, Pani B, Rajagopal S, Shenoy SK, Bouvier M, Benovic JL, Liggett SB, Ruffolo RR, Bristow MR, Packer M. How carvedilol does not activate ß(2)-adrenoceptors. Nat Commun. 2023 Nov 30;14(1):7866. PubMed PMID: 38036531

Diamond MG, Fiuzat M, Mentz RJ, Lala-Trindade A, Whellan DJ, Walsh MN, Costanzo MR, Yehya A, Desvigne-Nickens P, Malik F, O'Connor CM, Bristow MR. Rewarding Site-Based Research: A Step Toward Improving the Ecosystem of Heart Failure Clinical Trials. JACC Heart Fail. 2024 Jan;12(1):226-228. PubMed PMID: 37804314

Martin TG, Juarros MA, Cleveland JC Jr, Bristow MR, Ambardekar AV, Buttrick PM, Leinwand LA. Assessment of Autophagy Markers Suggests Increased Activity Following LVAD Therapy. JACC Basic Transl Sci. 2023 Sep;8(9):1043-1056. PubMed PMID: 37791310

Tatman PD, Kao DP, Chatfield KC, Carroll IA, Wagner JA, Jonas ER, Sucharov CC, Port JD, Lowes BD, Minobe WA, Huebler SP, Karimpour-Fard A, Rodriguez EM, Liggett SB, Bristow MR. An extensive ß1-adrenergic receptor gene signaling network regulates molecular remodeling in dilated cardiomyopathies. JCI Insight. 2023 Aug 22;8(16). PubMed PMID: 37606047

Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH, Johri S, Pursley MS, Gupta R, Meehan PS, Franchi F, Effron MB, Marshall D, Graybill CA, Huebler SP, Keuer T, Bristow MR, Bonaca MP. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arterioscler Thromb Vasc Biol. 2023 Aug;43(8):1572-1582. PubMed PMID: 37381988

Koupenova M, Chung MK, Bristow MR. COVID-19 and the Cardiovascular System: Requiem for a Medical Minotaur. Circ Res. 2023 May 12;132(10):1255-1258. PubMed PMID: 37167357

Altman NL, Berning AA, Mann SC, Quaife RA, Gill EA, Auerbach SR, Campbell TB, Bristow MR. Vaccination-Associated Myocarditis and Myocardial Injury. Circ Res. 2023 May 12;132(10):1338-1357. PubMed PMID: 37167355

Chevalier P, Roy P, Bessière F, Morel E, Ankou B, Morgan G, Halder I, London B, Minobe WA, Slavov D, Delinière A, Bochaton T, Paganelli F, Lesavre N, Boiteux C, Mansourati J, Maury P, Clerici G, Winum PF, Huebler SP, Carroll IA, Bristow MR. Impact of Neuroeffector Adrenergic Receptor Polymorphisms on Incident Ventricular Fibrillation During Acute Myocardial Ischemia. J Am Heart Assoc. 2023 Mar 21;12(6):e025368. PubMed PMID: 36926933

Annex BH, Bristow MR, Frangogiannis NG, Kelly DP, Kontaridis M, Libby P, MacLellan WR, McNamara CA, Mann DL, Pitt GS, Sipido KR. JACC: Basic to Translational Science Top Reviewers 2022: With Appreciation and Gratitude. JACC Basic Transl Sci. 2023 Feb;8(2):236. PubMed PMID: 36908670

Rubino M, Travers JG, Headrick AL, Enyart BT, Lemieux ME, Cavasin MA, Schwisow JA, Hardy EJ, Kaltenbacher KJ, Felisbino MB, Jonas E, Ambardekar AV, Bristow MR, Koch KA, McKinsey TA. Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart. Circ Res. 2023 Jan 6;132(1):10-29. PubMed PMID: 36475698

Altman NL, Berning AA, Saxon CE, Adamek KE, Wagner JA, Slavov D, Quaife RA, Gill EA, Minobe WA, Jonas ER, Carroll IA, Huebler SP, Raines J, Messenger JC, Ambardekar AV, Mestroni L, Rosenberg RM, Rove J, Campbell TB, Bristow MR. Myocardial Injury and Altered Gene Expression Associated With SARS-CoV-2 Infection or mRNA Vaccination. JACC Basic Transl Sci. 2023 Feb;8(2):124-137. PubMed PMID: 36281440

Fleming TR, Wittes J, Fiuzat M, Bristow MR, Frank W. Rockhold FW, Connor JT, Saville BR, Claggett B, Isabella Cavagna I, Abraham WT, Cook TD, 13, Lindenfeld J, O’Connor CM, , David L DeMets DL, on Behalf of the Heart Failure Collaboratory. Training the next generation of Data Monitoring Committee Members: An initiative of the Heart Failure Collaboratory. In press. 2024.

Professor, Medicine-Cardiology

Medical School

Graduate School

Internship

Residency

Fellowships

Languages

Department

Professional Titles

Recognitions

Publications

Professional Memberships

Practice Locations

Specialty Information

School of Medicine

CU Anschutz

Fitzsimons Building